Arikstra solution for infection. 12.5mg/ml attacked. syringe of 0.6 ml (7.5 mg) No. 10

Solution for Arikstr's injections is shown for treatment of an acute deep vein thrombosis, treatment of an acute pulmonary embolism, except as in hemodynamically unstable patients or patients for whom the thromboclasis or pulmonary embolectomy is necessary.

Structure

Active ingredient: fondaparinuks sodium;

1 syringe (0.4 ml) contains 5 mg of a fondaparinuks of sodium;

1 syringe (0.6 ml) contains 7.5 mg of a fondaparinuks of sodium;

1 syringe (0.8 ml) contains 10 mg of a fondaparinuks of sodium;

Excipients: sodium chloride, water for injections, sodium hydroxide or hydrochloric acid.

Contraindication

established an allergy to active ingredient or to any of medicament excipients. Active clinically significant bleeding. Acute bacterial endocarditis. Heavy renal failure (clearance of creatinine <30 ml/min.).

by

for a subcutaneous or intravenous injection. Not to apply intramusculary. Arikstra is intended only for use under control of the doctor.

Pregnant

it is not recommended by

Feature of use

Drivers

With care.

Overdose

can result Exceeding the recommended doses of medicament in the increased risk of developing of bleeding. There is no known antidote to a fondaparinuks.

in case of overdose, is followed by hemorrhagic complications, it is necessary to stop treatment and to find out a basic reason of bleeding. It is necessary to consider a question of purpose of the corresponding therapy, such as surgical hemostasis, completion of blood loss, transfusion is fresher than blood plasma, a plasma exchange.

Side effects

Most often the registered serious undesirable reactions at use of a fondaparinuks are hemorrhagic complications (in different sites, including exceptional cases intracranial/intracerebral and retroperitoneal bleedings) and anemia. Fondaparinuks patients should apply with care with the increased risk of developing of bleeding.

Interaction

Drugs increasing risk of bleeding should not be applied along with Arikstroy, except for antagonists of vitamin K, applied to treatment of a venous thrombembolia. If such combined use is necessary, it should be seen off under careful control.

to Store

at a temperature below 25 °C.

to Store

out of children's reach.

Expiration date - 3 years.